# OnCo record caspian (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/caspian/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "caspian", "NCT03043872" ;
  schema:name "CASPIAN"@en ;
  schema:description "Confirmed that adding a PD-L1 blocker to first-line chemotherapy helps in small-cell lung cancer, and showed that adding a second immunotherapy did not help further."@en ;
  schema:url <https://onco.cc/trials/caspian/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03043872> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2017-03-27" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/platinum-etoposide/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/luis-paz-ares/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/>, <https://onco.cc/key-papers/paper-caspian-lancet-oncol-2021-update/> .